5 recruiting, 5 unknown, 2 completed, 1 not yet recruiting. 14 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 5, Unknown 5, Completed 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 4 | Unknown 3, Recruiting 1 |
Follow Malignant Ascites: new trials by email Literature Review of Malignant Ascites trials Research Report on Malignant Ascites
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TLR9 Immunotherapy for Peritoneal Carcinomatosis ACM-CpG - Malignant Ascites, Colorectal Adenocarcinoma | Phase 1 | Recruiting | Brown University | 24 | 2026-08-25 | 2026-10-01 |
| WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I) WSK-IM02 - Advanced Solid Tumors, Malignant Pleural Effusions | Phase 1 | Not yet recruiting | WestVac Biopharma Co., Ltd. | 9 | 2026-06-01 | 2026-05-29 |
| Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab - Malignant Ascites | Phase 1 / Phase 2 | Recruiting | Dong sheng Zhang | 48 | 2025-11-28 | 2026-02-09 |
| A Phase I Study of SIM0388 in Participants With Malignant Ascites. SIM0388 - Malignant Ascites | Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd. | 50 | 2025-04-24 | 2025-06-06 |
| Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Tocilizumab - Malignant Pleural Effusion, Malignant Ascites | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 12 | 2024-01-30 | 2025-05-22 |
| A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer T3011 - Malignant Ascites | Phase 1 | Unknown | West China Hospital | 10 | 2023-09-28 | 2024-01-11 |
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases Dual-targeting VEGFR1/PD-L1 CAR-T cells - Malignant Peritoneal Effusion, Malignant Ascites | Phase 1 | Recruiting | Sichuan University | 40 | 2023-02-15 | 2026-08-13 |
| PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 40 | 2022-09-01 | 2022-08-15 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites SCB-313 - Malignant Ascites | Phase 1 | Completed | Sichuan Clover Biopharmaceuticals, Inc. | 13 | 2019-09-28 | 2022-05-06 |
| A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites BSG-001 - Malignant Pleural Effusion, Malignant Ascites | Phase 1 / Phase 2 | Unknown | BioSyngen Pte Ltd | 58 | 2019-01-01 | 2018-11-08 |
| A Study of M701 (EpCAM and CD3) in Malignant Ascites Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701 - Malignant Ascites, Cancer | Phase 1 | Completed | Wuhan YZY Biopharma Co., Ltd. | 35 | 2018-09-30 | 2025-07-17 |
| Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Erythrocytes derived MPs containing MTX, convention drugs - Malignant Ascites | Phase 1 / Phase 2 | Unknown | Hui ting Xu，MD | 18 | 2017-05-01 | 2017-07-26 |
| A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Cinobufacini Injection - Digestive System Cancer, Malignant Ascites | Phase 1 | Unknown | Dongfang Hospital Beijing University of Chinese Medicine | 48 | 2015-07-01 | 2017-08-30 |
| Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Intraperitoneal Bevacizumab - Malignant Ascites | Phase 1 | Terminated | Eastern Regional Medical Center | 10 | 2015-06-01 | 2017-07-12 |
Pleural Effusion, Malignant (3) · Neoplasms (2) · Adenocarcinoma, Mucinous (1) · Digestive System Neoplasms (1) · Meningeal Carcinomatosis (1) · Neoplasm Metastasis (1) · Peritoneal Neoplasms (1)
Neoplasms by Site (6) · Neoplasms (5) · Pleural Diseases (3) · Pleural Effusion (3) · Pleural Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Digestive System Diseases (2) · Abdominal Neoplasms (1) · Adenocarcinoma (1) · Carcinoma (1) · Central Nervous System Neoplasms (1) · Digestive System Neoplasms (1) · Meningeal Neoplasms (1)
ACM-001 COVID-19 vaccine (1) · Bevacizumab (1) · huachansu (1) · irinotecan sucrosofate (1) · molgramostim (1) · regramostim (1) · tocilizumab (1)
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · BioSyngen Pte Ltd (1) · Brown University (1) · Dong sheng Zhang (1) · Dongfang Hospital Beijing University of Chinese Medicine (1) · Eastern Regional Medical Center (1) · Hui ting Xu，MD (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Second Affiliated Hospital of Soochow University (1) · Sichuan Clover Biopharmaceuticals, Inc. (1) · Sichuan University (1) · West China Hospital (1) · WestVac Biopharma Co., Ltd. (1) · Wuhan YZY Biopharma Co., Ltd. (1)
China (9) · United States (3) · Australia (1)
Jianming Xu (1) · Khaldoun Almhanna, MD (1) · Lietao Li, MD (1) · Patrick Wagner, MD (1) · Shixuan Wang (1) · Yongsheng Wang, Prof. (1)